Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 6188-25-6 | MDL No. : | MFCD05663807 |
Formula : | C7H5ClN2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | XQEGYCZJSVFGEE-UHFFFAOYSA-N |
M.W : | 152.58 | Pubchem ID : | 2764328 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 40.2 |
TPSA : | 17.3 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.53 cm/s |
Log Po/w (iLOGP) : | 1.88 |
Log Po/w (XLOGP3) : | 2.39 |
Log Po/w (WLOGP) : | 1.99 |
Log Po/w (MLOGP) : | 1.32 |
Log Po/w (SILICOS-IT) : | 1.63 |
Consensus Log Po/w : | 1.84 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.96 |
Solubility : | 0.168 mg/ml ; 0.0011 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.39 |
Solubility : | 0.615 mg/ml ; 0.00403 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.68 |
Solubility : | 0.316 mg/ml ; 0.00207 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.53 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
5.10 g | at 80℃; for 16 h; | A mixture of A-1 (4.50 g, 35.00 mmol) and 2-chloroacetaldehyde (10.30 g, 52.50 mmol, 8.45 mL) in EtOH (50.00 mL) and H20 (10 mL) was stirred at 80 °C for 16 hours The mixture was concentrated to a residue that was diluted with 0 (100 mL) and extracted with EtOAc (150 mL x 2). The combined organic phase was washed with water (50 mL x 2) and brine (20 mL), dried over Na2S04, filtered and concentrated to afford A-2 (5.10 g, 33.43 mmol) as a solid. H NMR (400 MHz, CDC13) δΗ 8.18 (d, 1H), 7.65 (s, 1H), 7.59 - 7.50 (m, 2H), 7.12 (dd, 1H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
900 mg | With N-iodo-succinimide In N,N-dimethyl-formamide at 0 - 20℃; for 16 h; | To a mixture of A-2 (500.00 mg, 3.28 mmol) in DMF (10 mL) was added NIS (884.70 mg, 3.94 mmol) at 0 °C. The mixture was allowed to warm to 20 °C and stir for 16 hours. Sat.NaHCC (20 mL) was then added, and the mixture was stirred for 1 hour. The solid was collected by filtration and dried in oven to afford A-3 (900.00 mg, 3.23 mmol) as a solid. H NMR (400 MHz, CDC13) δΗ 8.20 (s, 1H), 7.72 (s, 1H), 7.57 (d, 1H), 7.21 (dd, 1H). |
[ 1005785-45-4 ]
6-Chloroimidazo[1,2-a]pyridin-2-amine
Similarity: 0.89
[ 4532-25-6 ]
7-Chloroimidazo[1,2-a]pyridine
Similarity: 0.89
[ 29096-59-1 ]
6-Chloroimidazo[1,2-a]pyridine-3-carbaldehyde
Similarity: 0.84
[ 858516-69-5 ]
6,8-Dichloroimidazo[1,2-a]pyridine
Similarity: 0.84
[ 886371-28-4 ]
3-Bromo-6-chloroimidazo[1,2-a]pyridine
Similarity: 0.84
[ 1005785-45-4 ]
6-Chloroimidazo[1,2-a]pyridin-2-amine
Similarity: 0.89
[ 4532-25-6 ]
7-Chloroimidazo[1,2-a]pyridine
Similarity: 0.89
[ 858516-69-5 ]
6,8-Dichloroimidazo[1,2-a]pyridine
Similarity: 0.84
[ 886371-28-4 ]
3-Bromo-6-chloroimidazo[1,2-a]pyridine
Similarity: 0.84